Personalized treatment after surgery for early breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study checks whether adding a personalized (biomarker-matched) medicine after standard chemotherapy and surgery lowers the risk of breast cancer coming back. Your study drug choice depends on tumor test results (from your tumor’s genetics and immune markers).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have early breast cancer that has not spread to other organs
- You already had chemotherapy before surgery (neoadjuvant), then surgery, then the usual additional treatment afterward
- Your cancer type matters: if it is not the “fully cleared” response (non-pCR), you must meet the study’s specific post-surgery stage rules
- For hormone-receptor–positive, HER2-negative cancer, your tumor must meet the study’s CPS-EG score AND node status rules
- You must be well enough to travel and take study pills (performance status 0–1) and recover from side effects of prior treatment
- Blood tests and organ function (bone marrow, kidney, liver) must meet required lab ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This study tests different treatment plans given before surgery for early breast cancer that is both hormone receptor-positive and HER2-positive. The goal is to see which treatment is more effective and to tailor it to each patient.
This trial tests two medicines after surgery and chemotherapy to help lower the risk that triple-negative breast cancer comes back. It’s for people whose cancer still showed “residual” invasive disease after neoadjuvant (before-surgery) chemotherapy, and whose blood test shows traces of tumor DNA.
Hear when a new Early-stage Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.